Preliminary Third Quarter Revenues of Approximately $625 Million Preliminary Third Quarter GAAP EPS range of $1.67-$1.69 and Adjusted EPS range of $1.75-$1.77 Management to Discuss Financial Results and Outlook on Third Quarter Earnings Call on November 2, 2023

BDC

Why This Fisker Analyst Is Bullish After Q2 Earnings

By Lisa Levin

August 4, 11:26 AM

Fisker Inc’s (NYSE: FSR) second-quarter results were slightly better than expected, with lower operating expenses than anticipated, according to RBC Capital Markets.

FSR

Moleculin Granted FDA Fast Track Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme

By Benzinga Newsdesk

December 7, 9:47 AM

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,

MBRX

Morgan Stanley Downgrades Five9 to Equal-Weight

Related Posts

Morgan Stanley Maintains Equal-Weight on Cummins, Raises Price Target to $264

Belden Sees Preliminary Q3 Adj. EPS $1.75-$1.77 From $1.75-$1.85 Vs $1.82 Est; Now Sees Revenue ~$625M From $675M-$690M Vs $685.19M Est

Why This Fisker Analyst Is Bullish After Q2 Earnings

Moleculin Granted FDA Fast Track Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme